Overview
The Pharmacist’s Role in Managing Patients with Worsening Heart Failure
Digital Interactive FAQ
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Pharmacists play a vital role in the management of patients with heart failure (HF). Navigate through this interactive self-directed, pharmacist-targeted activity designed to optimize your decision-making to apply the most recent clinical trial data and guidance seen in real-world HF practice, particularly in patients with worsening HF and after recent HF hospitalization. Expert perspectives and insights cover guideline-directed medical therapy (GDMT) implementation and additional adjustment therapies to improve patient quality of life, hospitalization rates, and mortality risks in your patients with worsening HF.
This activity is designed for clinical and hospital pharmacists, who manage patients with heart failure.
Heart failure (HF) is a leading cause of hospitalization, and recurrent hospitalization is associated with persistent or worsening HF. Pharmacists play a vital role in the management of patients with HF, including medication initiation, dose titration and adjustment, medication reconciliation, and transitions of care. Additionally, for patients with worsening HF, cardiologists often collaborate with pharmacists, who can monitor patients more frequently and help them achieve their goals. Through this interactive, self-directed activity, pharmacists can easily access the latest evidence and guidance to support collaborative medication management and optimal use of guideline-driven therapy in patients with worsening HF and after recent HF hospitalization.
Upon completion of this activity, learners will be able to:
- Describe unmet needs and clinical practice gaps for complex patients with worsening HF
- Describe the impact of worsening heart failure on healthcare utilization and patient outcomes
- Recognize the effectiveness of novel therapies for patients who continue to experience symptoms and hospitalization due to worsening HF
- Employ pharmacist-led interventions to optimally introduce novel therapies into treatment paradigms for HF
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an independent medical educational grant from Merck & Co., Inc..
Topic #1: Guideline-Directed Medical Therapy (GDMT) for Heart Failure With Reduced Ejection Fraction (HFrEF)
Topic #2: Individualized Management for Patients With Worsening HFrEF
Topic #3: Opportunities With New and Emerging Therapies for Worsening HFrEF
Topic #4: Role of the Pharmacist on the collaborative Management Team
Topic #2: Individualized Management for Patients With Worsening HFrEF
Topic #3: Opportunities With New and Emerging Therapies for Worsening HFrEF
Topic #4: Role of the Pharmacist on the collaborative Management Team
Cait E. Kulig, PharmD, HF-Cert
Cardiology Clinical Pharmacist
Inpatient Cardiothoracic Surgery/Cardiology Outpatient Clinic
St. Joseph's University Medical Center
Paterson, NJ
Clinical Assistant Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, NJ
Cardiology Clinical Pharmacist
Inpatient Cardiothoracic Surgery/Cardiology Outpatient Clinic
St. Joseph's University Medical Center
Paterson, NJ
Clinical Assistant Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, NJ
B. Andrew Mardis, PharmD, BCCP, BCTXP, BCPS
Clinical Pharmacy Specialist, Advanced Heart Failure
Director, PGY2 Cardiology Pharmacy Residency
Prisma Health–Midlands
Columbia, SC
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Cait E. Kulig, PharmD, HF-Cert (Faculty)
No financial relationships to disclose.
B. Andrew Mardis, PharmD, BCCP, BCTXP, BCPS
Speakers' Bureau: AstraZeneca, Boehringer-Ingelheim
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Karen Catino at kcatino@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1 contact hour.
ACPE Universal Activity Number: 0396-0000-23-005-H01-P
Activity Type: Application
Release Date: June 16, 2023
Expiration Date: June 16, 2024
CPE credit will be submitted to CPE Monitor® on the first business day of each month.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
